MAPT and Alzheimer disease: While recent advancements in PET imaging have enabled 3-D in vivo visualization of Aβ and tau pathology, there are currently no established imaging biomarkers available to specifically detect non-AD co-pathologies in vivo, although cerebrospinal fluid measures are emerging for detecting α-synuclein pathology28.